Last reviewed · How we verify

NCT06553924

Macitentan and Tadalafil Film-coated Tablets 10 mg/40 mg and 'PrOpsynvi®' Macitentan and Tadalafil Film-coated Tablets 10 mg/40 mg

Completed Phase 1 Last updated 14 August 2024
What this trial tests

Phase 1 trial testing Macitentan and Tadalafil film-coated tablets in PAH in 30 participants. Completed in 8 August 2024.

Timeline
14 May 2024
Primary endpoint
31 May 2024
8 August 2024

Quick facts

Lead sponsorHumanis Saglık Anonim Sirketi
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposeother
Enrollment30
Start date14 May 2024
Primary completion31 May 2024
Estimated completion8 August 2024
Sites1 location across India

Drugs / interventions tested

Conditions studied

Sponsor

Humanis Saglık Anonim Sirketi — full company profile →

Who can join

Adults 18 to 55, any sex, with PAH. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Single dose oral bioequivalence study of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg and 'PrOpsynvi®' Macitentan and Tadalafil film-coated tablets 10 mg/40 mg in healthy adult male subjects under fasting conditions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Humanis Saglık Anonim Sirketi trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06553924.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing